MindMed has officially been added to the NASDAQ Global Market.
On April 22nd, MindMed filed an 8-A12B with the SEC which ultimately allowed it to uplist to the NASDAQ. For NEO owners, the ticker symbol will remain MMED, for OTC owners, it’ll change to MNMD.
On 23rd of April, MindMed announced that as onf April 27th MindMed will be trading as MNMD on the NASDAQ. This means that MindMed was able to meet financial and listing requirements. Typically when securities get listed on major stock exchanges, they are highly traded and prices higher than those that trade OTC. Being able to uplist and trade on an exchange such as the NASDAQ will provide MindMed exposure and visibility to a larger market which might, in the short term, 2, 3 or 4x MindMed’s stock price as more people buy the stock due to FOMO. This happened when Compass Pathways IPOed which almost 4xed its share price within a few days from $17 to $60 before CMPS dropped back down to $33.
Where does MindMed go from here on? MMEDF is just at the beginning of their long-term growth trajectory. Some investors might feel inclined to take profits, which is absolutely understandable. However, like I’ve been saying in the majority of my MindMed episodes or any psychedelic stock videos, the potential returns could be a lot higher in a few years, when/if MindMed shows proof that their medicines work and gets FDA approval.
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#MindMed #MindMedNasdaq #MindMedstock
Psychedelic Spotlight is your reliable source for the latest stories in the emerging psychedelics industry, covering breakthrough discoveries, investor news and cultural reform.
By signing up to the Psychedelic Spotlight newsletter you agree to receive electronic communications from Psychedelic Spotlight that may sometimes include advertisements or sponsored content.